Technology

Verrica Pharmaceuticals

$10.89
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.90 (-7.63%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell VRCA and other stocks, options, and ETFs commission-free!

About VRCA

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA. The listed name for VRCA is Verrica Pharmaceuticals Inc. Common Stock.

CEO
Ted White
Employees
17
Headquarters
West Chester, Pennsylvania
Founded
2013
Market Cap
251.10M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
73.05K
High Today
$11.73
Low Today
$10.76
Open Price
$11.61
Volume
65.98K
52 Week High
$17.60
52 Week Low
$6.02

Collections

VRCA Earnings

-$0.42
-$0.28
-$0.14
-$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, Pre-Market

You May Also Like

OTRAU
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure